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Summary
 
The pleiotrophic but overlapping functions of the cytokine family that includes interleukin
(IL)-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and car-
diotrophin 1 are mediated by the cytokine receptor subunit gp130 as the common signal trans-
ducer. Although mice lacking individual members of this family display only mild phenotypes,
animals lacking gp130 are not viable. To assess the collective role of this cytokine family, we
inducibly inactivated gp130 via Cre-loxP–mediated recombination in vivo. Such conditional
mutant mice exhibited neurological, cardiac, hematopoietic, immunological, hepatic, and pul-
monary defects, demonstrating the widespread importance of gp130-dependent cytokines.
Key words: gene targeting • conditional gene targeting • Cre/loxP technology • 
gp130-dependent cytokines • gp130
 
T
 
he cytokine network contains various cytokine fami-
lies whose members share a common subunit in their
receptor complexes (1). One family of cytokines, compris-
ing IL-6, IL-11, leukemia inhibitory factor (LIF),
 
1
 
 oncosta-
tin M (OSM), ciliary neurotrophic factor (CNTF), and
cardiotrophin 1 (CT-1), share the common signal trans-
ducer gp130 in their receptors. Individual components of
these cytokine receptor complexes are IL-6R
 
a
 
, IL-11R
 
a
 
,
CNTFR
 
a
 
, CT-1R
 
a
 
, LIFR, and OSMR. Signal transduc-
tion after ligand binding is elicited by homodimerization of
gp130 in the case of IL-6 and IL-11, by heterodimerization
of gp130 and LIFR in the case of LIF, CNTF, and CT-1,
or by heterodimerization of gp130 and OSMR in the case
of OSM (2, 3). Thereby, the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) pathway (JAK1/
JAK2/TYK2 and STAT1/STAT3/STAT5B) and the RAS/
mitogen-activated protein kinase (RAS-MAPK) pathway
are activated (2).
Mice lacking individual components of this cytokine fam-
ily or their receptors (IL-6, LIF, CNTF, or IL-11R
 
a
 
) dis-
played milder phenotypes than expected. This is most likely
due to the redundancy of gp130-dependent cytokines (4–7).
The only phenotype exhibited by mice lacking IL-11R
 
a
 
 is
female sterility (7, 8). IL-6–deficient animals exhibit defects
in hematopoiesis (9), antigen-specific antibody production
(except IgM; 4, 10), neutrophilia after infection (11, 12),
T
 
H
 
1 development (12, 13), chemokine induction and leuko-
cyte recruitment (14), acute phase protein (APP) synthesis
(4, 15), hepatocyte regeneration (16), fever response (17),
neuroglial activation (18), and bone maintenance (19) and
display an increased susceptibility to infections with viral,
bacterial, fungal, and protozoan pathogens (4, 11–13). LIF-
deficient animals exhibit female sterility due to defective
blastocyst implantation, postnatal growth retardation, and
defects in hematopoiesis and thymocyte proliferation (5, 20).
Not surprisingly, when receptor components used by
several members of the gp130 family are inactivated, the
consequences are more severe. Thus, mutant animals lack-
ing LIFR, a shared component of the receptor complexes
 
1
 
Abbreviations used in this paper:
 
 APP, acute phase protein(s); CNTF, ciliary
neurotrophic factor; CT-1, cardiotrophin 1; JAK, Janus kinase; LIF, leu-
kemia inhibitory factor; MAPK, mitogen-activated protein kinase; OSM,
oncostatin M; s, soluble; SAP, serum amyloid 
 
P
 
; STAT, signal transducer
and activator of transcription; VSV, vesicular stomatitis virus.
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for LIF, CNTF, and CT-1, are not viable and die perina-
tally, exhibiting placental, skeletal, neural, and metabolic
defects as well as a loss of motor neurons (21, 22). Although
CNTF-deficient mice are only marginally affected by a
gradual loss of motor neurons, animals lacking CNTFR
 
a
 
die postnatally (6, 23), suggesting that the CNTFR
 
a
 
 has
more than one ligand. Animals deficient for the common
signal transducer gp130 die after day 12.5 postconception
or postnatally, depending on the genetic background (24,
25). These embryos exhibit growth retardation, decreased
hematopoiesis in the fetal liver, and reduced numbers of
primordial germ cells. In addition, they also show a dis-
rupted placental architecture, a hypoplastic ventricular my-
ocardium, and an increased number of osteoclasts (24, 25).
Due to the redundancy of gp130-activating cytokines on
one hand and premature lethality of animals lacking shared
receptor components on the other, it has so far been im-
possible to assess the collective physiological role of gp130-
dependent cytokines in the adult animal. To answer this
question, we inactivated the common signal transducer
gp130 inducibly by conditional gene targeting after postna-
tal lethality had been bypassed (26).
 
Materials and Methods
 
Mice
 
C57BL/6 mice were obtained from Charles River GmbH
(Sulzfeld, Germany), and IL-6–deficient mice were provided by
H. Mossmann (MPI für Immunologie, Freiburg, Germany). All
animals were kept under standard conditions and maintained on
acidified water.
 
Flow Cytometry
 
Staining was done with fluorochrome (FITC, PE, or Cy-
Chrome) or biotin-conjugated mAbs for flow cytometric analysis
on a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA). Bi-
otin-conjugated mAb was detected using streptavidin-PE (South-
ern Biotechnology Associates, Inc., Birmingham, AL). mAb spe-
cific for gp130 (RX187) was a gift from K.-I. Akamatsu (Chugai
Pharmaceutical Co. Ltd., Tokyo, Japan). mAbs were purchased
from PharMingen (San Diego, CA) or Serotec Ltd. (Oxford, UK).
 
Hematologic Analysis
 
Blood was taken from mouse tail vein, diluted with PBS, and
leukocyte, erythrocyte, and thrombocyte counts were determined
by cell counter (model STKS; Coulter Corp., Hialeah, FL). GM-
CFU were measured using methylcellulose medium supplemented
with recombinant cytokines (Methocult GF M3434; CellSystems,
Biotechnologie Vertrieb GmbH, Remagen, Germany) according
to the manufacturer’s instructions.
 
Soluble gp130 ELISA
 
The concentration of soluble gp130 (sgp130) in the blood was
determined using a sandwiched ELISA. Plates were coated with
anti-gp130 mAb (RX435) to capture sgp130 from the mouse
serum. The presence of bound sgp130 was detected with biotiny-
lated anti-gp130 antibody (RX187 [27]) followed by streptavidin-
conjugated alkaline phosphatase (Boehringer Mannheim, Mann-
heim, Germany). Recombinant sgp130 was used as a standard.
 
Measurement of Acute Phase Response after LPS Injection
 
Mice were injected intraperitoneally with 1 mg LPS purified
from 
 
Escherichia coli
 
 (Sigma, Deisenhofen, Germany) per kg body
wt. Hematic glucose was measured using a Glucometer 3 (Bayer
Figure 1. Gene targeting. (a)
Gene targeting vector (bold
line) homologously recombined
into the gp130 locus (dashed line),
thereby generating the targeted
allele gp130NEO3loxP. Exon se-
quences (rectangles); loxP sites
(triangles). The transcriptional
orientation of the neomycin re-
sistance gene is shown. Restric-
tion sites used for Southern anal-
ysis are given; those marked with
an asterisk are not present in the
wild-type locus but are intro-
duced via the targeting vector.
The probes used for Southern
analysis are shown (black). In the
gp130NEO2loxP allele, the loxP site
upstream of exon 16 is missing
due to lack of cointegration. (b)
Southern analysis to identify
homologous recombinant clones.
The size and position of the
bands representing the gp1301
(wild-type) and gp130targeted
(gp130NEO2loxP or gp130NEO3loxP)
alleles are given. (c) Southern analysis to identify clones harboring a cointegrated upstream loxP site. The position and size of the bands representing the
gp130NEO2loxP and gp1301 alleles or the gp130NEO3loxP allele are given. (d) Southern analysis to identify clones which have deleted the neomycin resistance
gene but not exon 16 after transient expression of Cre-recombinase. The position and size of the bands representing the gp1301, gp130flox, and
gp130NEO3loxP alleles are given. (e) Southern blot prepared with mouse tail DNA in order to genotype the animals. The position and size of the bands
representing the gp1301, gp130flox, and gp130D alleles are shown. Lane 4: bal1, Cre-transgenic (reference 31). 
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Diagnostic GmbH, München, Germany). The concentration of
serum amyloid 
 
P
 
 (SAP) and C3 in the serum was measured by
ELISA using sheep anti–mouse SAP antiserum (Calbiochem
Novabiochem GmbH, Bad Soden, Germany), rabbit anti–mouse
SAP antiserum (Calbiochem Novabiochem GmbH), alkaline
phosphatase–conjugated goat anti–rabbit IgG antiserum (Promega
Deutschland GmbH, Mannheim, Germany), goat anti–mouse C3
antiserum (Organon Teknika-Cappel, Durham, NC), and perox-
idase-conjugated goat anti–mouse C3 antiserum with a SAP/C3
standard as a reference (Calbiochem Novabiochem GmbH).
 
Serum Antibody Levels
 
The concentrations of the different Ig isotypes in the serum
were determined by ELISA as described previously (28).
 
Fixation Procedure
 
After anesthesia, the lung was perfusion-fixed with 4% para-
formaldehyde for 20 min at 15 cm H
 
2
 
O using an intratracheal
catheter. Subsequently, mice were transcardially perfused using
the same fixative at a perfusion pressure of 60 cm H
 
2
 
O for the
same time. Organs were removed and fixed for an additional 4 h
in the same fixative.
 
Light and Electron Microscopy
 
4% paraformaldehyde perfusion-fixed mouse tissue was post-
fixed with 2% osmium tetroxide in 0.1 M PBS for 2 h at 4
 
8
 
C. Af-
ter a thorough wash in 0.1 M phosphate buffer for 10 min three
times, the slices were dehydrated in a graded ethanol series and
infiltrated with and embedded in araldite. Sections of plastic-
embedded specimens were cut with a glass or diamond knife on a
Reichert ultramicrotome.
 
Morphometric Study
 
For quantification of the ventricular wall thickness, a 2-mm
slice perpendicular to the heart axis at the upper half of the ven-
tricular region was cut out, divided in four pieces, and measured
in five randomly selected parts of both ventricles at two planes.
The myocyte width was measured perpendicular to the long axis
of the myocyte slice on 60 randomly selected myocytes of each
ventricle using Optimas 6.0. Quantification of the binucleated
hepatocytes was performed on methylene blue–stained semithin
sections of three specimens from different parts of the liver. 100
hepatocytes of 10 randomly selected areas were counted.
 
Infection Experiments
 
Vaccinia.
 
Mice were infected intravenously with 2 
 
3 
 
10
 
6
 
PFU vaccinia-WR. Viral titers in the lungs were determined at
day 5 after infection by plaquing 10-fold dilutions of tissue ho-
mogenates on monolayers of BSC40 cells, followed by crystal vi-
olet staining after 48 h.
 
Vesicular Stomatitis Virus.
 
Mice were infected intravenously
with 2 
 
3 
 
10
 
6 
 
PFU vesicular stomatitis virus, strain Indiana (VSV-
IND). Mice were bled on days 4, 8, 12, and 20 after infection,
and VSV-neutralizing Ig and IgG antibodies were determined as
described (29). The titer was determined by twofold dilution
steps of 1:40 prediluted sera, and reduction of IgM was achieved
by treating the sera with 0.1 M 2-ME. Titer is defined as the dilu-
tion that reduced the number of plaques to half of the control.
 
Listeria.
 
Mice were infected intravenously with 3 
 
3 
 
10
 
3 
 
CFU
 
Listeria monocytogenes
 
. The number of viable bacteria recovered
from liver and spleen was determined 5 d after infection by plat-
ing 10-fold serial dilutions of organ homogenates on brain–heart
infusion agar plates.
 
Results
 
Generation of a Mouse Line Allowing for Conditional Inacti-
vation of gp130.
 
A targeting vector was constructed in
which the exon encoding the transmembrane region of
gp130 was flanked with two loxP sites (Fig. 1 
 
a
 
). Homolo-
gous recombinant E14 embryonic stem cell colonies were
generated (Fig. 1 
 
b
 
) which had cointegrated the upstream
loxP site (allele: gp130
 
NEO3loxP
 
) (Fig. 1 
 
c
 
). After transient trans-
fection with the Cre-encoding plasmid pICCre, clones were
Figure 2. Inactivation of gp130. (a) Southern blot prepared with DNA
of various organs of an adult Mx-cre;gp130flox/flox mouse injected postna-
tally with IFN to induce expression of Cre-recombinase. The Southern
blot was performed as described in Fig.1 e. (b) Concentration of sgp130 in
the blood of wild-type, heterozygous, or homozygous gp130flox animals
(shaded circles) and heterozygous gp130D animals (open circles) as measured
by ELISA. One symbol represents data obtained for one animal. (c) Cell
surface expression of gp130 on peripheral blood CD81 T cells of adult
gp130flox/flox (black line), gp130D/flox (gray line), and Mx-cre;gp130flox/flox an-
imals which were injected with IFN as newborns (gray histogram). 
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identified which had deleted neo
 
r
 
 but not the transmembrane
exon (Fig. 1 
 
d
 
 [30]). The resulting allele (gp130
 
flox
 
) can be
inactivated by Cre-loxP–mediated recombination (thereby
generating gp130
 
D
 
) through removal of the transmembrane
exon and a resulting frame shift. Embryonic stem cells were
injected into C57BL/6 blastocysts. Resulting chimeric
mice were crossed with C57BL/6 animals to establish mice
carrying the gp130
 
flox
 
 mutation in the germ line (Fig. 1 
 
e
 
).
As mice homozygous for the gp130
 
flox
 
 allele were pheno-
typically indistinguishable from wild-type animals, the in-
troduction of loxP sites apparently did not affect gp130 ex-
pression significantly. To inactivate the loxP-flanked allele
in the germ line, gp130
 
flox/flox
 
 animals were crossed to Bal1
cre-transgenic mice (31).
 
Inducible Inactivation of gp130. To allow for inducible
inactivation of gp130, gp130flox/flox animals were crossed to
Figure 3. Degeneration of pe-
ripheral nerves in conditional
gp130-mutant mice. Electron
microscopic analysis of periph-
eral somatic nerves innervating
skeletal muscle (A–D) and vege-
tative nerves innervating the
heart muscle (E and F) or gut (G
and H) of control gp130flox/flox (A
and  E) and conditional gp130-
mutant animals (B–D, F–H). A,
Axon;  S,  Schwann cell; P ,  cell
body. (A) Control, skeletal mus-
cle: the myelinated nerve fibers
show a regular myelin and axon
structure (A). (B) Conditional
gp130-mutant, skeletal muscle:
disappearance of laminar myelin
structure (arrow) without signs of
axon lysis. (C) Conditional
gp130-mutant, skeletal muscle: in
certain areas the myelin sheath
shows a complete lysis (arrow).
(D) Conditional gp130-mutant,
skeletal muscle: the degeneration
of the myelin sheath (arrow) is as-
sociated with an axon lysis (A*).
(E) Control, heart: the axon
bundle has a complete and intact
Schwann cell covering (S). (F)
Conditional gp130-mutant, heart:
the axon bundle (A) shows a par-
tial failure of Schwann cell cov-
ering, while the basal lamina
completely surrounds it. (G)
Conditional gp130-mutant, gut:
also in a thicker axon bundle of
the gut an incomplete covering of
the axon (A) by Schwann cells (S)
is recognizable. (H) Conditional
gp130-mutant, gut: the glia (S)
covering of a myenteric neuron’s
cell body (P) shows no signs of
alteration. For A–D, bar (in D) 5
1  mm; for E–G, bar (in G)  5
0.25 mm; for H, bar 5 1.5 mm.1959 Betz et al.
mice expressing Cre-recombinase under control of the
IFN-responsive Mx1 promoter (Mx-cre [32]). 1–3 d after
birth, mice were injected with 5 3 106 U IFN-a2/a1 to
induce Cre-mediated recombination (33). 3–4 wk later,
mice were genotyped and tested for the efficiency of Cre-
mediated deletion by Southern or FACSÒ analysis using
anti-gp130 antibody (RX187 [27]). Cre-mediated deletion
of the loxP-flanked allele was close to completion in he-
matopoietic cells and in hepatocytes, whereas the extent of
deletion varied in other organs between 20 and 70% (Fig. 2
a). Possible side effects of IFN-a treatment do not pose a
problem for our analysis of the resulting phenotype, as the
conditional mutants were compared with control animals
that likewise received a postnatal IFN-a injection (34).
The gp130D Allele Is Nonfunctional. As expected from
the removal of the transmembrane region, in the blood of
animals carrying a gp130D allele, the concentration of
sgp130 was 20-fold increased compared with gp1301/1 or
gp130flox/flox controls (Fig. 2 b). In inter-crosses between
heterozygous gp130D mice, no viable gp130D/D animals were
obtained. gp130D/D embryos could be found up to day 18.5
after conception but were severely reduced in size com-
pared with their wild-type or heterozygous littermates (not
shown). As measured by FACSÒ on T cells, gp130 surface
expression was only marginally reduced in gp130D/flox com-
pared with gp130flox/flox mice, whereas cells were gp1302
after Cre-mediated recombination in Mx-cre;gp130flox/flox
animals (Fig. 2 c).
Accordingly, Mx-cre;gp130flox/flox mice treated with
IFN-a2/a1 as newborns are hereafter referred to as condi-
tional gp130-mutants. These animals exhibited a diverse
phenotype, were weight-reduced, and had a reduced life
span, with 50% of the animals dying before the age of 5 mo
(not shown).
gp130 Deficiency Leads to Schwann Cell Decomposition and
Degeneration of Both Myelinated and Unmyelinated Peripheral
Nerves. gp130-dependent cytokines have been shown to
play an important role in the generation and maintenance
of motor neurons (6, 21, 23, 35). Interestingly, in periph-
eral somatic nerves innervating skeletal leg muscle (muscu-
lus gastroceminus), conditional gp130-mutant mice exhib-
ited a degeneration of the myelin sheath (Fig. 3, A–D).
The defects on the myelin sheath ranged from disappear-
ance of the laminar structure (Fig. 3 B) to complete loss of
myelin (Fig. 3, C and D) and axon lysis (Fig. 3 D). In myo-
cardium as well as in the gut, Schwann cell covering of
some small and thick axon bundles was also incomplete in
the conditional mutants (Fig. 3, F and G). However, in
contrast to the axon terminals, most cell bodies showed an
unaltered glia covering (Fig. 3 H). This result shows that
gp130-dependent cytokines in adult animals not only influ-
ence the survival of motor neurons, as described in mice
deficient for CNTF or CNTF/LIF, but also affect Schwann
cell covering in myelinated and unmyelinated peripheral
nerves.
Myocardial Abnormalities in Conditional gp130-mutant
Mice. Although the efficiency of Cre-mediated recombi-
nation in the heart was low (20–30%; see also Fig. 2 a),
distinct morphological alterations were apparent. In the
cardiac ventricles of conditional mutant animals, a subpop-
ulation of cardiomyocytes exhibiting a reduction in diame-
ter was detectable. In the left ventricle, for example, 16% of
the myocytes from conditional gp130-mutant animals
showed a diameter ,10 mm, compared with only 2.8% in
controls. In addition, conditional gp130-mutants exhibited
a thinning of the left (from 792 6 149 to 619 6 101 mm)
and right (from 344 6 56 to 248 6 48 mm) ventricular
wall of the heart, and in some cases right ventricular dila-
Figure 4. Hematopoietic de-
fects in the absence of functional
gp130. Conditional gp130-mutant
(shaded symbols); gp130flox/flox (filled
symbols). (a) Basal hematology
profile. The number of leuko-
cytes, erythrocytes, and thromb-
ocytes was determined in blood
collected from the tail vein. (b)
Recovery after 5-FU–induced
hematopoietic ablation. The ki-
netics of recovery of leukocytes,
erythrocytes, and thrombocytes
in the peripheral blood after a sin-
gle intraperitoneal administration
of 150 mg/kg 5-FU at day 0 was
determined over a period of 30 d
(n 5 7 for each genotype). (c)
Survival after immune thrombo-
cytopenia. Thrombocytopenia
was induced by intraperitoneal
injection of 3 ml adsorbed rabbit
anti–mouse platelet serum (Inter-
Cell Technologies, Inc., Hope-
well, NJ) diluted in PBS at day 0,
and survival of animals was subse-
quently monitored.1960 Conditional Inactivation of the gp130 Gene
tion (not shown). As a cardiac defect was also detected in
the conventional gp130-deficient embryos (24), this result
shows that gp130-dependent cytokines affect cardiomyo-
cyte proliferation or maintenance beyond embryonic de-
velopment.
Defects in Hematopoiesis in the Absence of gp130-mediated
Signals. An influence of gp130-dependent cytokines on
hematopoiesis is well established. It was also apparent in
mice deficient for IL-6 or LIF, although numbers of circu-
lating white and red blood cells and thrombocytes were still
normal (9, 20). In contrast, conditional gp130-mutant mice
displayed a reduction in thrombocyte count in the periph-
eral blood together with an increased number of circulating
leukocytes, which is unexplained at the moment. Red
blood cell counts were normal (Fig. 4 a). To further assess
the role of gp130 in hematopoiesis, we abrogated hema-
topoiesis by 5-fluoro-59-deoxyuridine (5-FU) treatment,
which kills cycling cells (Fig. 4 b), and determined the abil-
ity of the mutant mice to recover. Although leukocytes
were generated efficiently in the conditional gp130-mutant
animals, resynthesis of erythrocytes and thrombocytes was
impaired. A defect in thrombocyte synthesis in the condi-
tional gp130-mutant animals was also apparent after induc-
tion of thrombocytopenia by administration of antithromb-
ocyte antiserum, which could not be compensated for by
the mutant animals (Fig. 4 c).
The number of hematopoietic precursors (CFU-S, GM-
CFU) was reduced by 40% in the bone marrow of condi-
tional mutants, whereas in the spleen a twofold increased
number of GM-CFU could be detected (not shown).
However, the reduction in hematopoietic precursors was
more dramatic in gp130-deficient embryos (24).
Accordingly, gp130-dependent cytokines seem to be
critically important for establishing the hematopoietic com-
partment during embryogenesis or after hematopoietic ab-
lation. Under steady state conditions, they continue to play
a major role in thrombopoiesis.
IL-6 Is the Principal Member of gp130-dependent Cytokines
in the Immune System. In accordance with what is seen in
IL-6–deficient mice (4), T cell content in conditional
gp130-mutant animals was reduced by 30%, whereas B cell
development was not affected. Although IL-6 has been
considered to be essential for the terminal differentiation of
B cells into Ig-secreting plasma cells (36), mice lacking IL-6
surprisingly displayed normal total serum antibody levels
(4). Likewise, in conditional gp130-mutants, no general
defect in antibody production could be detected and anti-
body levels were not reduced compared with controls (Fig.
5). However, the mutants exhibited increased levels of
IgG1 and IgE in the blood, indicative for increased IL-4
production, as demonstrated previously in the IL-2–defi-
cient mouse mutant (37).
To directly compare the ability of IL-6–deficient and
conditional gp130-mutant mice to control infections with
viral and bacterial pathogens, we infected animals with
VSV, vaccinia virus, and L. monocytogenes. During VSV in-
fection, production of virus-neutralizing IgG was reduced
by three- to fourfold in conditional gp130-mutant animals,
as in IL-6–deficient mice (Fig. 6 a), whereas no significant
difference in neutralizing IgM level was detected (Fig. 6 b).
Infection with the cytopathic vaccinia virus is controlled by
the soluble mediators IFN-g and TNF-a, rather than cyto-
toxic T cells (38–40). 5 d after infection with vaccinia vi-
Figure 5. Antibody production in conditional gp130-mutant animals.
Levels of different Ig isotypes in 12–15-wk-old conditional gp130-mutant
(open circles) and gp130flox/flox animals (filled circles) as quantitated by ELISA.
One symbol represents data obtained for one animal.
Figure 6. Increased susceptibility to viral and bacterial infections of
conditional gp130-mutant animals. (a and b) The anti-VSV IgG (a) and
IgM (b) response after infection was determined as described in Materials
and Methods in conditional gp130-mutant (open circles), IL-6–deficient
(shaded circles), and gp130flox/flox (filled circles) control animals (at least three
per group and time point). (c) The number of vaccinia virus recovered
from lung at day 5 after infection (see Materials and Methods) was deter-
mined in conditional gp130-mutant (open circles), IL-6–deficient (shaded
circles), and gp130flox/flox (filled circles) control animals. One symbol repre-
sents data obtained from one mouse. (d) The number of viable L. monocy-
togenes in the spleen 5 d after infection (see Materials and Methods) was
determined in conditional gp130-mutant (open circles), IL-6–deficient
(shaded circles), and gp130flox/flox (filled circles) control animals. One symbol
represents data obtained from one mouse.1961 Betz et al.
rus, viral titers in the lung were increased by a factor of 10–
30 in conditional gp130-mutant and IL-6–deficient mice
compared with gp130flox/flox controls (Fig. 6 c). Infections
with L. monocytogenes are controlled by neutrophilic granu-
locytes and macrophages and cleared by a T cell–dependent
mechanism (41). Also in this case, the pathogen titer was
increased 10–20-fold in spleen (Fig. 6 d) of conditional
gp130-deficient animals 5 d after infection, again as ob-
served in IL-6–deficient mice.
In summary, the immune system of gp130-deficient ani-
mals does not seem to be more severely affected than it is in
IL-6–deficient animals. Thus, our data suggest that IL-6 is
the principal member of the gp130-dependent cytokine
family with regard to immune function.
Morphologic Abnormalities in the gp130-mutant Liver Are Ac-
companied by a Decreased Ability to Synthesize APP. gp130-
dependent cytokines have been reported to play a major
role in liver regeneration and APP synthesis (4, 15, 16, 42).
gp130-mutant livers exhibited a decreased content of binu-
cleated hepatocytes (12.2% compared with 21.4% in con-
trols). Further signs of liver abnormalities in the mutant an-
imals (Fig. 7) were an increased number of Kupffer cells, a
scarce content of rough and smooth endoplasmic reticu-
lum, an increase of lipid vacuoles, an increase of laminar
bodies, a widening of the Disse space and intercellular
space between hepatocytes, dense clustering of mitochon-
dria, reduction and morphological alteration of microvilli,
and a shift in glycogen particles from the rosette a to the
monoparticulate b form. However, mitochondria and bile
canaliculi were indistinguishable in mutant and wild-type
liver. In older mice, part of the gp130-mutant liver tissue
was replaced by fibrotic tissue (Fig. 7, C and D).
These drastic morphological changes were reflected by a
severely decreased ability to synthesize APP. 24 h after intra-
peritoneal injection of LPS, control animals displayed a con-
siderable increase in the concentration of the APP SAP and
Figure 7. Hepatic abnormalities in the
conditional mutants. Light (A–D) and elec-
tron (E and F) microscopic analysis of con-
trol (A, C, and E) and gp130-mutant (B, D,
and F) liver. N, Nucleus; S, liver sinus. Af-
ter 6 wk, gp130-mutant liver (B) has a high
amount of lipid droplets (arrowheads), wid-
ening of the Disse and intercellular space
(arrows), a reduced content of binucleated
hepatocytes, and an increase in Kupffer cells
compared with controls (A). In 12-mo-old
gp130-mutant liver, a part of the liver pa-
renchyma is replaced by fibrotic material
(D, arrows), a phenomenon not observed in
the gp130flox/flox control animals (C). The
ultrastructure of gp130-mutant liver (F)
gives evidence for a rarification of smooth
and rough endoplasmic reticulum (ER), a
dense clustering of mitochondrial (Mi) and
monoparticulate (b) glycogen granules (tri-
angle), a decrease of microvilli (*), and an
enlargement of Disse and intercellular spaces
(arrows) compared with the gp130flox/flox
control (E). For A and B, bar 5 5 mm; for
C and D, bar 5 20 mm; for E and F, bar 5
0.5 mm.1962 Conditional Inactivation of the gp130 Gene
complement C3 in the blood. Yet, the conditional gp130-
mutant animals failed to do so (Fig. 8 a). Monitoring SAP
and blood glucose levels revealed that this was not simply
due to a delay in APP synthesis in the mutants (Fig. 8 b).
Conditional gp130-mutant Mice Develop Emphysema with
Increasing Age. Investigation of the lungs revealed the de-
velopment of emphysema with increasing age in the condi-
tional gp130-mutant animals. At the age of 6 wk, no sign
of emphysema formation or elastin degradation was observ-
able (not shown). Although after 5 mo only a scarce alter-
ation of lung morphology could be observed on methylene
blue–stained sections of the mutants, there was a distinct
reduction of elastic fibers, as demonstrated by orcein stain-
ing (Fig. 9, A and B). However, at the age of 12 mo, a dis-
tinct emphysema could be observed in the conditional
gp130-mutants, which exhibited an enlargement of the aci-
nus and destruction of respiratory tissue associated with
fibrosis (Fig. 9, C and D ). Thus, the mutant animals
displayed a time-dependent reduction of elastic fibers, fol-
lowed by the development of lung emphysema, a pheno-
type unprecedented in the available mutant mice lacking
individual components of the gp130–cytokine system.
Discussion
Degeneration of Peripheral Nerves in the Absence of gp130-
mediated Signals. The progressive degeneration of periph-
eral nerves starting with Schwann cell degradation (Fig. 3)
cannot be explained by an inflammatory process due to in-
creased pathogen susceptibility of gp130-mutant animals, as
the tissue surrounding the damaged nerves did not show
any morphologic alterations and the defects are uniform in
peripheral vegetative nerve systems, in myocardic and
enteric systems, and in somatic nerves in skeleton muscle.
As no Schwann cell defect has been described to date in
conjunction with the motor neuron deficits of CNTF- or
LIF/CNTF-deficient mice (6, 35), it is conceivable that an
as yet uncloned ligand is the main mediator for gp130 sig-
nals on Schwann cells. Alternatively, the observed defect
may become apparent only after simultaneous inactivation
of several gp130-dependent cytokines, as various family
members have been reported to enhance the survival of
oligodendrocytes in vitro (43).
gp130 Signals Are Important for Thrombopoiesis. The anal-
ysis presented here points to a special importance of gp130-
dependent cytokines for the synthesis of thrombocytes, as
already under steady state conditions thrombocyte number
was reduced in the absence of functional gp130 (Fig. 4). It
has been shown previously that IL-6, IL-11, LIF, OSM, IL-3,
and thrombopoietin can increase platelet production (44).
In addition, IL-6 transgenic mice showed an increase in the
number of mature multinuclear megakaryocytes in the
bone marrow (45). Nevertheless, neither IL-6–, IL-11R–,
nor LIF-deficient mice displayed decreased platelet counts,
although IL-6–deficient mice had lower numbers of CFU-
MK (9). The redundant function of gp130-dependent cy-
tokines with regard to thrombocyte production is reflected
by the fact that inactivation of gp130 produced a more se-
vere phenotype than inactivation of any single ligand.
Redundancy among Different gp130-dependent Cytokines
Does Not Play a Major Role in the Immune System. The ef-
fects of gp130 deficiency in the immune system do not
seem to be more severe than those caused by the absence of
IL-6 alone, as judged by T cell numbers, total Ig content in
the blood (Fig. 5), antigen-specific antibody production,
and susceptibility to infection by viral and bacterial patho-
gens (Fig. 6). This argues against a major regulatory role of
gp130-dependent cytokines in the immune system apart
from IL-6, indicating that redundancy among different
family members is not widespread in the regulation of im-
munity. Also, gp130 inactivation was very efficient; in he-
matopoietic cells, the possibility exists that remaining wild-
type cells were selected during immune responses, thereby
attenuating the phenotype displayed by the conditional
mutants.
gp130 Plays a Major Role in the Acute Phase Response and
Lung Physiology. The importance of IL-6 for hepatocytes
has only been apparent under stress conditions, e.g, pro-
voked by localized tissue damage or partial hepatectomy (4,
15, 16). In contrast, in the absence of gp130, profound histo-
logical changes arose spontaneously in the liver (Fig. 7).
Likewise, although APP production after injection of LPS
was almost normal in IL-6–deficient mice (4, 15), in gp130-
Figure 8. No increased synthesis of APP in the absence of functional
gp130. (a) Conditional gp130-mutant (gray bars, n 5 5) and gp130flox/flox
control mice (black bars, n 5 5) were injected intraperitoneally with 1 mg/kg
LPS, and the concentration of the APP SAP and C3 in the serum was
measured 24 h later by ELISA. (b) The hematic glucose and serum SAP
concentrations were monitored over a period of 80 h after challenge with
1 mg/kg LPS in gp130-mutant (shaded symbols) and control (filled symbols)
animals.1963 Betz et al.
mutant mice no increased synthesis of APP could be de-
tected (Fig. 8). This could reflect a specific role of gp130-
dependent cytokines other than IL-6 in the induction of APP
synthesis or a general synthetic deficiency of gp130-deficient
hepatocytes, which exhibit drastic morphological alterations
including an underdeveloped endoplasmic reticulum.
Conditional gp130-mutant animals developed emphy-
sema with increasing age, starting with elastic fiber degra-
dation (Fig. 9). If neutrophil elastase activity during infec-
tions cannot be efficiently held in check by antiproteases,
which are a major component of the APP, elastin digestion
and finally emphysema development results (46). Accord-
ingly, humans suffering from congenital a1-antitrypsin de-
ficiency suffer from emphysema with increasing age (47).
In this regard, it is interesting to note that apart from hepa-
tocytes, lung epithelial cells are also a source of antipro-
teases. Here synthesis can be stimulated by OSM, but not
by other gp130-dependent cytokines (47, 48). This predicts
that OSM-deficient or OSM/IL-6 double mutant animals
may likewise suffer from emphysema development.
Concluding Remarks. Taken together, we were able to
assess the function of gp130 by ablating the common signal
transducer gp130 in mice after birth. The observed demy-
elination of peripheral nerves, thrombocytopenia, the dis-
rupted liver architecture in combination with an impaired
acute phase response, and the formation of emphysema in
the lung did not occur in animals lacking individual mem-
bers of the gp130-dependent cytokine family generated to
date. Thus, either these effects become apparent only when
several gp130-dependent cytokines have been inactivated
simultaneously or they are due to uncharacterized family
members. The diverse phenotype of conditional gp130-
mutant animals demonstrates the widespread importance of
gp130-dependent cytokines, and points to their potential
therapeutic use in conditions such as emphysema forma-
tion, thrombocytopenia, and nerve degeneration.
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Figure 9. Emphysema development in
conditional gp130-mutant animals. Repre-
sentative histological appearance of lungs
from different ages of gp130flox/flox and con-
ditional gp130-mutant mice. (A and B) Or-
cein staining. After 5 mo of age, conditional
gp130-mutants (B) showed a distinct reduc-
tion of elastic fibers (red) compared with
controls (A). (C and D) Methylene blue
staining. At the age of 12 mo, a distinct rari-
fication of alveolar walls was detectable in
the absence of functional gp130 (D) com-
pared with gp130flox/flox controls (C). Bar 5
60 mm.1964 Conditional Inactivation of the gp130 Gene
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